Clinical Trial Update: Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating tolerability and safety of recombinant human acid sphingomyelinase in acid sphingomyelinase deficiency patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acid Sphingomyelinase Deficiency
• Niemann-pick Disease

Drugs mentioned

• recombinant human acid sphingomyelinase (recombinant human acid sphingomyelinase)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Human Acid Sphingomyelinase Deficiency | Phase 1 | Status: COMPLETED